UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of evolocumab in patients on high- vs moderate-intensity background statin therapy

Atherosclerosis, 2016-09, Vol.252, p.e230-e231

2016

Volltextzugriff (PDF)

Evolocumab use in Greece is associated with early and sustainable reductions in low-density cholesterol (LDL-C) and high persistence to therapy: Results from the Greek cohort analysis of the observational HEYMANS study

Hellenic journal of cardiology, 2023-11, Vol.74, p.74-76

2023

Volltextzugriff (PDF)

The efficacy of evolocumab and other lipid-lowering therapies (LLT) for the management of low density lipoprotein cholesterol (LDL-C): a systematic review and network meta-analysis (NMA)

Atherosclerosis, 2016-09, Vol.252, p.e56-e57

2016

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH MIXED HYPERLIPIDEMIA

Canadian journal of cardiology, 2015-10, Vol.31 (10), p.S294-S295

2015

Volltextzugriff (PDF)

Keep Off My (Virtual) Lawn: Encroachment in the Age of the Internet

Franchise law journal, 2017-01, Vol.36 (3), p.415-428

Bridges, Emily I.

2017

Volltextzugriff (PDF)

Safety of very low LDL-C levels with evolocumab: An analysis from the pan-European observational HEYMANS study

Atherosclerosis, 2023-08, Vol.379, p.S43

2023

Volltextzugriff (PDF)

AB0884 Disease outcomes in patients with psoriatic arthritis completing 12 months of apremilast treatment - Real-world data from the REWARD study

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.1565-1566

2022

Volltextzugriff (PDF)

An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months

Clinical nephrology, 2011-03, Vol.75 (3), p.242-250

2011

Volltextzugriff (PDF)

Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients

Clinical nephrology, 2009-04, Vol.71 (4), p.397-404

2009

Volltextzugriff (PDF)

Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

High long-term persistence to evolocumab treatment regimens in European clinical practice: analysis of the HEYMANS registry

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

Evolocumab use and LDL-C lowering in a cohort of european patients with familial hypercholesterolemia (FH) - Results from the Heymans study

Atherosclerosis, 2021-08, Vol.331, p.e253-e253

2021

Volltextzugriff (PDF)

Issuer Beware: The Varied Landscape of State "Baby-CARD" Laws

Franchise law journal, 2016-06, Vol.36 (1), p.69-86

2016

Volltextzugriff (PDF)

Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study

European heart journal, 2020-11, Vol.41 (Supplement_2)

2020

Volltextzugriff (PDF)

What potential risk reduction could be achieved with evolocumab treatment? A simulation based on observational data from a cohort of users in 10 European countries

European heart journal, 2020-11, Vol.41 (Supplement_2)

2020

Volltextzugriff (PDF)

Final results from the pan-European observational heymans study suggest a mismatch between guidelines and PCSK9i reimbursement criteria

Atherosclerosis, 2022-08, Vol.355, p.14

2022

Volltextzugriff (PDF)

Baseline characteristics of bulgarian patients prescribed evolocumab in clinical practice

Atherosclerosis, 2020-12, Vol.315, p.e212-e212

2020

Volltextzugriff (PDF)

Potential cardiovascular risk reduction with evolocumab in the real world: a simulation in patients with a history of myocardial infarction from the HEYMANS register

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

Evolocumab use in Europe: clinical guidelines vs. reimbursement thresholds – results from the HEYMANS study

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

Franchising & Distribution Currents

Franchise law journal, 2019-06, Vol.39 (1), p.113-148

2019

Volltextzugriff (PDF)

Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

P1699Characteristics of patients prescribed Evolocumab in Europe. Does clinical use match clinical guidelines?

European heart journal, 2018-08, Vol.39 (suppl_1)

2018

Volltextzugriff (PDF)

P654Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice

European heart journal, 2019-10, Vol.40 (Supplement_1)

2019

Volltextzugriff (PDF)

Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study

European cardiology, 2023, Vol.18, p.e36-e36

2023

Volltextzugriff (PDF)

Effect of evolocumab on cognition in pediatric patients with familial hypercholesterolemia: Results from the HAUSER-RCT study

Atherosclerosis, 2021-08, Vol.331, p.e258-e258

2021

Volltextzugriff (PDF)

1 – 25 von 20.336

Suche als RSS-Feed

Aktive Filter

SpracheChinesisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13.307)
Mit Volltextzugriff
(15.107)

Publikationsform

9 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(7.424)
Life Sciences & Biomedicine
(5.221)
Humans
(3.404)
Female
(1.866)
Male
(1.746)
Animals
(1.703)
Biological And Medical Sciences
(1.565)
Physical Sciences
(1.457)
Social Sciences
(1.186)
Technology
(1.106)
Medical Sciences
(943)
Adult
(927)
Middle Aged
(805)
Fundamental And Applied Biological Sciences. Psychology
(666)
Aged
(605)
Physics
(580)
Rats
(535)
Exact Sciences And Technology
(519)
Engineering
(497)
General & Internal Medicine
(465)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(5.695)
Ingenta.com
(5.570)
MEDLINE
(5.048)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(4.223)
Publisher or Other Site
(3.560)
Access via ScienceDirect (Elsevier)
(2.705)
Access via Wiley Online Library
(2.408)
JSTOR
(2.119)
IngentaConnect Journals
(2.055)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1.998)
Ebook Central Perpetual and DDA
(1.477)
Wiley Online Library
(1.336)
eBooks on EBSCOhost
(1.335)
Nexis Uni
(1.019)
Oxford Journals
(976)
SAGE Journals Online
(835)
SpringerLink
(832)
Taylor & Francis Online
(813)
Taylor & Francis
(807)
Access via Taylor & Francis
(750)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of evolocumab in patients on high- vs moderate-intensity background statin therapy

Evolocumab use in Greece is associated with early and sustainable reductions in low-density cholesterol (LDL-C) and high persistence to therapy: Results from the Greek cohort analysis of the observational HEYMANS study

The efficacy of evolocumab and other lipid-lowering therapies (LLT) for the management of low density lipoprotein cholesterol (LDL-C): a systematic review and network meta-analysis (NMA)

EFFICACY AND SAFETY OF THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH MIXED HYPERLIPIDEMIA

Keep Off My (Virtual) Lawn: Encroachment in the Age of the Internet

Safety of very low LDL-C levels with evolocumab: An analysis from the pan-European observational HEYMANS study

AB0884 Disease outcomes in patients with psoriatic arthritis completing 12 months of apremilast treatment - Real-world data from the REWARD study

An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months

Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients

Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry

High long-term persistence to evolocumab treatment regimens in European clinical practice: analysis of the HEYMANS registry

Evolocumab use and LDL-C lowering in a cohort of european patients with familial hypercholesterolemia (FH) - Results from the Heymans study

Issuer Beware: The Varied Landscape of State "Baby-CARD" Laws

Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study

What potential risk reduction could be achieved with evolocumab treatment? A simulation based on observational data from a cohort of users in 10 European countries

Final results from the pan-European observational heymans study suggest a mismatch between guidelines and PCSK9i reimbursement criteria

Baseline characteristics of bulgarian patients prescribed evolocumab in clinical practice

Potential cardiovascular risk reduction with evolocumab in the real world: a simulation in patients with a history of myocardial infarction from the HEYMANS register

Evolocumab use in Europe: clinical guidelines vs. reimbursement thresholds – results from the HEYMANS study

Franchising & Distribution Currents

Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia

P1699Characteristics of patients prescribed Evolocumab in Europe. Does clinical use match clinical guidelines?

P654Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice

Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study

Effect of evolocumab on cognition in pediatric patients with familial hypercholesterolemia: Results from the HAUSER-RCT study

Aktive Filter

Suchergebnisse filtern